Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

AutoInflammatory Disease Alliance Registry (AIDA)

Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic/multifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings. In this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.

Who May Be Eligible (Plain English)

Who May Qualify: - to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype; - to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and/or classification criteria; - to be diagnosed with undifferentiated systemic AID; - to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria; - to be diagnosed with anterior or posterior non-infectious scleritis; - to be diagnosed with spondyloarthritis according to ASAS and/or New York criteria; - to be diagnosed with Castleman disease; Who Should NOT Join This Trial: \- willing to sign a consent form/assent not provided by the patient and/or his/her legal representative. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype; * to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and/or classification criteria; * to be diagnosed with undifferentiated systemic AID; * to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria; * to be diagnosed with anterior or posterior non-infectious scleritis; * to be diagnosed with spondyloarthritis according to ASAS and/or New York criteria; * to be diagnosed with Castleman disease; Exclusion Criteria: \- informed consent/assent not provided by the patient and/or his/her legal representative.

Treatments Being Tested

OTHER

No intervention is foreseen by the protocol.

Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.

Locations (20)

University Algiers 1
Algiers, Algeria
Université M'Hamed Bougara de Boumerdas
Boumerdas, Algeria
Flinders University
Adelaide, Australia
University of Adelaide
Adelaide, Australia
Antwerp University Hospital
Antwerp, Belgium
Hospital das Clinicas da Faculdade de Medicina HCFMUSP
São Paulo, Brazil
Peking University People's Hospital
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Universidad del Rosario - Escuela de Medicina Y Ciencias de La Salud
Bogotá, Colombia
Mansoura University, Faculty of Medicine
Al Mansurah, Egypt
Al-Azhar University
Cairo, Egypt
Cairo University
Cairo, Egypt
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Evangelismos General Hospital
Athens, Greece
National and Kapodistrian University of Athens
Athens, Greece
National and Kapodistrian University of Athens
Athens, Greece
Prabha Eye Clinic & Research Centre
Bangalore, India
Postgraduate Institute of Medical Education and Research
Chandigarh, India
Shariati Hospital - Tehran University of Medical Sciences
Tehran, Iran
Azienda Ospedaliero-Universitaria Senese
Siena, Tuscany, Italy